| ▲ | therein 5 days ago |
| I like how they aren't saying Semaglutide in the title in an attempt to perhaps keep it from immediate scrutiny. |
|
| ▲ | rzzzt 5 days ago | parent | next [-] |
| The first link goes to the study and it does mention the ingredient: https://www.sciencedirect.com/science/article/pii/S2452302X2... |
| |
| ▲ | therein 5 days ago | parent [-] | | I am talking about UAlberta's title specifically. | | |
| ▲ | rzzzt 5 days ago | parent [-] | | "Semaglutide Reduces Cardiomyocyte Size and Cardiac Mass in Lean and Obese Mice" was also written by UoA researchers. I don't see anything nefarious in the choice of the title for the news blurb. |
|
|
|
| ▲ | skeaker 5 days ago | parent | prev | next [-] |
| More likely because the average reader won't know what that is versus the current title which succinctly summarizes it. |
|
| ▲ | neom 5 days ago | parent | prev [-] |
| https://www.fda.gov/drugs/postmarket-drug-safety-information... Same thing?? |
| |
| ▲ | TylerE 5 days ago | parent | next [-] | | No. That’s talking about the compounded versions (NOT in an auto pen) that were temporarily allowed due to shortages, but whose authorization has since been revoked. | |
| ▲ | therein 5 days ago | parent | prev [-] | | > Unapproved GLP-1 Drugs Used for Weight Loss
Yeah that would be perfect. But editorializing it to the point of calling it `weight loss drug`, just feels like it is begging for the reaction of "oh yet another weight loss drug". |
|
